METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) TESTING SYSTEMS MARKET ANALYSIS

Market Challenges And Opportunities

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market– Drivers

Increasing prevalence of methicillin resistant staphylococcus aureus infection

The increasing prevalence of methicillin resistant staphylococcus aureus infection is expected to drive the global methicillin resistant staphylococcus aureus (MRSA) testing systems market growth over the forecast period. For instance, according to the U.S. Department of Health and Human Services report of March 2021, nearly 320,000 staphylococcus aureus bloodstream infections and 50,000 associated deaths occurred in the U.S. in 2020. After years of slow progress, the rate of decline of MRSA bloodstream infections has slowed, but bloodstream infections caused by methicillin-susceptible staphylococcus aureus in hospitals are increasing day by day in the community.

Products approvals by regulatory bodies

Products approvals by regulatory bodies are expected to accelerate the methicillin resistant staphylococcus aureus (MRSA) testing systems market growth in the forecast period. For instance, in April 2021, Luminex Corporation, a biotechnology company which develops, manufactures, and markets proprietary biological testing technologies in the U.S., announced that the company had received the U.S. Food and Drug Administration (FDA) 510(k) clearance for the ARIES MRSA Assay. The assay is an integrated, real-time, polymerase chain reaction (PCR) based, qualitative, in vitro diagnostic test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. Luminex ARIES System is an instrument designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into the modern laboratory.

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market: Restraint

Product Recall of Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems  

Product recall of methicillin resistant staphylococcus aureus (MRSA) testing systems is expected to hamper the growth of the global methicillin resistant staphylococcus aureus (MRSA) testing systems market over the forecast period. For instance, in June 2021, the U.S. FDA initiated a product recall on Becton Dickinson & Company is medical technology company that manufactures and sells medical devices, instrument systems, and reagents, BD Max MRSA test kit because the foil bags containing extraction tubes for BD MAX reagent products may not be sealed properly which lead to false representation of test results. An advisory has been released to all the users of BD Max instruments within testing facilities to ensure awareness and prevent false test results.

Key Players are focusing on quality, safety and efficacy of products.

• Product recall of Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems